BioMarin Pharmaceutical Inc. (NAS: BMRN) Stock Analysis & Fundamentals

BMRNBioMarin Pharmaceutical Inc.

NAS · US · Healthcare · Biotechnology · biomarin.com

60.00USD+1.78%Mkt Cap: 11.60B $P/E: 43.171d ago

BioMarin Pharmaceutical Inc., a biotechnology company, engages in the development and commercialization of therapies for life-threatening rare diseases and medical conditions in the United States, Europe, Latin America, …

Headline	Source	Time
This week
FDA Accepts BMRN's sNDA Seeking Full Approval for Voxzogo BioMarin's FDA filing for full Voxzogo approval in achondroplasia has been accepted, with a regulatory decision expected by Feb. 28, 2027.	Zacks	Jul 14
BioMarin Pharmaceutical (BMRN) Following Its VOXZOGO FDA Filing And The Case For Undervaluation BioMarin Pharmaceutical (BMRN) stock is back in focus after the FDA accepted the company’s supplemental New Drug Application for VOXZOGO, with a target decision date set for February 28, 2027. See our latest analysis for BioMarin Pharmaceutical. BioMarin Pharmaceutical’s recent FDA filing comes after a period where momentum has picked up, with a 30 day share price return of 5.81% and a 90 day share price return of 6.72%, although the 3 year total shareholder return is still down 31.69%. If...	Simply Wall St.	Jul 13
1 of Wall Street’s Favorite Stocks with Competitive Advantages and 2 We Avoid Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.	StockStory	Jul 13
Older
Beyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?	Trefis	Jul 10
Collect 9.0% On VRTX Stock Now, And Still Keep 15% Of Upside	Trefis	Jul 8
2 Cash-Heavy Stocks with Exciting Potential and 1 We Ignore	StockStory	Jun 29
2 Healthcare Stocks for Long-Term Investors and 1 We Brush Off	StockStory	Jun 26
Therapeutics Stocks Q1 Teardown: BioMarin Pharmaceutical (NASDAQ:BMRN) Vs The Rest	StockStory	Jun 25
ABCELLERA BIOLG (ABCL) Surges 7.1%: Is This an Indication of Further Gains?	Zacks	Jun 25
BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment	Insider Monkey	Jun 23
2 Profitable Stocks Worth Your Attention and 1 We Find Risky	StockStory	Jun 11
Biomarin Pharmaceutical (BMRN): Most Undervalued Stocks to Buy and Hold for 2 Years	Insider Monkey	Jun 8
BioMarin’s VOXZOGO Win In Hypochondroplasia Shapes Rare Disease Growth Story	Simply Wall St.	Jun 5
BioMarin (BMRN) Up 0.2% Since Last Earnings Report: Can It Continue?	Zacks	Jun 3
Centene, Deckers and 14 Other ‘Dividend Hopefuls’	Barrons.com	Jun 2
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year	Motley Fool	May 30
BioMarin Pharmaceutical Inc. (BMRN) A Stock that Could 10x by 2030 on Pipeline Development	Insider Monkey	May 30
JPMorgan says large-cap biotech is back as profits and pipelines fuel upside	Investing.com	May 28
Why BioMarin Pharmaceutical (BMRN) Stock Is Trading Up Today	StockStory	May 23
1 Small-Cap Stock with Solid Fundamentals and 2 We Find Risky	StockStory	May 22
BioMarin’s (BMRN) Phase 3 Trial of BMN 401 for ENPP1 Deficiency Meets One Co-Primary Endpoint	Insider Monkey	May 21
BioMarin (BMRN) Is Down 6.3% After Mixed Phase 3 BMN 401 Results in ENPP1 Deficiency	Simply Wall St.	May 20
BMRN Stock Down on Mixed Results From Rare Disease Therapy Study	Zacks	May 19
StubHub, Jazz Pharmaceuticals upgraded: Wall Street's top analyst calls	The Fly	May 19
Here Are Tuesday’s Top Wall Street Analyst Research Calls: American Tower, Citigroup, CrowdStrike, Fortinet, Hanover Insurance, Jazz Pharmaceuticals, Stubhub, X-Energy, and More	24/7 Wall St.	May 19
BioMarin drug acquired in buyout misses goal in rare disease study	BioPharma Dive	May 19
2 Cash-Producing Stocks Worth Investigating and 1 We Turn Down	StockStory	May 18

Industry Peers